Staphylococcus aureus immune globulin - Inhibitex

Drug Profile

Staphylococcus aureus immune globulin - Inhibitex

Alternative Names: SA-IGIV

Latest Information Update: 28 Jul 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Inhibitex
  • Class Antibacterials; Immunoglobulins; Polyclonal antibodies
  • Mechanism of Action Cell adhesion molecule inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Staphylococcal infections

Most Recent Events

  • 28 Jul 2004 Discontinued - Phase-II for Staphylococcal infections in USA (unspecified route)
  • 18 Oct 2002 No development reported - Phase-II for Staphylococcal infections in USA (unspecified route)
  • 13 Apr 2000 Phase-II clinical trials for Staphylococcal infections in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top